Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-09-30

Study Completion Date

2004-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women

NCT00005768

Menopause

UNKNOWN PHASE2

Aging and Estrogen on Cortical Function

NCT01268046

Memory Loss Cognitive Changes Postmenopausal Symptoms

COMPLETED PHASE1/PHASE2

Alzheimer's Disease Prevention Trial

NCT00000176

Alzheimer Disease Memory Disorders

COMPLETED PHASE3

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157

Alzheimer Disease

COMPLETED PHASE2/PHASE3

Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

NCT00018343

Alzheimer's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Estrogen (EST) may have significant benefits in preserving cognitive functioning in normal aging after menopause and in decreasing the incidence of Alzheimer's disease (AD). On a molecular level, EST has effects on a variety of cholinergic neuronal and receptor-mediated mechanisms that may be responsible for these beneficial effects. These neurons have critical relevance for the development of age-related cognitive changes and dementing disorders. However, little is known about the clinical relevance of EST-cholinergic interactions, either in normal aging or in AD.

The primary goal of this study is to test the hypothesis that three months of administration of EST to 1) normal post-menopausal women, and 2) female patients with mild-moderate AD who are concurrently treated with anticholinesterase therapy (donepezil), will positively change or blunt the negative and behavioral effects of drugs that block central cholinergic receptors (both muscarinic and nicotinic). Participants will be blindly placed on EST or placebo for three months each. After each three month period, they will be cognitively assessed after receiving single doses of the cholinergic antagonists scopolamine and mecamylamine. These results will have direct implications for the use of EST in post-menopausal women as well as interactive treatment with cholinergic drugs for AD. Researchers plan to recruit a total of 45 women (30 healthy, and 15 patients with AD).

NOTE: This study is only recruiting participants with Alzheimer's Disease at this time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Donepezil

Intervention Type DRUG

Estrogen

Intervention Type DRUG

Progesterone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal volunteers and women with mild Alzheimer's disease:
* Non-smoker
* No use of Hormone Replacement Therapy for at least one year
* No menses for at least one year
* Normal mammogram within the last year
* minimum age is 45 for patients with Alzheimer's disease; 50 for normal volunteers
* Maximum age is 85 for patients with Alzheimer's disease; there is no maximum age for normal volunteers.